Calcimedica presents aki data from a post-hoc analysis of the phase 2 cardea trial of auxora™ in severe covid-19 pneumonia at the 30th international aki & crrt conference

62.7% relative reduction in mortality at day 30, which persisted through day 60, for patients treated with auxora versus placebo in subset of patients in cardea with aki la jolla, calif. , march 4, 2025 /prnewswire/ -- calcimedica inc. ("calcimedica" or the "company") (nasdaq: calc), a clinical-stage biopharmaceutical company focused on developing novel calcium release-activated calcium (crac) channel inhibition therapies for acute and chronic inflammatory and immunologic illnesses, today announced that sudarshan hebbar, m.d.
CALC Ratings Summary
CALC Quant Ranking